Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials

IMPORTANCE: The optimal sequencing of immune checkpoint inhibitors and targeted therapy for BRAF V600E/K-mutant melanoma is not well established. OBJECTIVE: To assess the association of BRAF wild-type (WT) or BRAF V600E/K-mutant status and BRAF inhibitor (BRAFi) with or without MEK inhibitor (MEKi)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Oncol
Autors principals: Puzanov, Igor, Ribas, Antoni, Robert, Caroline, Schachter, Jacob, Nyakas, Marta, Daud, Adil, Arance, Ana, Carlino, Matteo S., O’Day, Steven J., Long, Georgina V., Margolin, Kim A., Dummer, Reinhard, Schadendorf, Dirk, Lutzky, Jose, Ascierto, Paolo A., Tarhini, Ahmad, Lin, Jianxin, Mogg, Robin, Homet Moreno, Blanca, Ibrahim, Nageatte, Hamid, Omid
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2020
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7366279/
https://ncbi.nlm.nih.gov/pubmed/32672795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.2288
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars